News and Scientific Presentations

Empirium

Hemab’s scientific legacy in action. Explore our complete collection of presentations and publications documenting our journey to advance understanding of overlooked bleeding disorders.

Categories

Presentation
July 14, 2026
July 14, 2026

ISTH 2026: Substantial Bleeding Burden and Limited Prophylaxis Use in Glanzmann Thrombasthenia

Read more
Presentation
May 6, 2023
July 22, 2025

Nordic Platelet Symposium: HMB-001 | A Novel Bispecific Antibody Accumulating and Targeting Endogenous FVIIa to Activated Platelets for Subcutaneous Prophylaxis in Multiple Bleeding Disorders Including Glanzmann Thrombasthenia

Presented at 2023 Nordic Platelet Symposium
Read more
Presentation
January 25, 2023
July 22, 2025

BSHT 2023: HMB-001 - a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets supports enhanced haemostatic responses in models of Glanzmann’s thrombasthenia

Presented at the 2023 British Society for Haemostasis & Thrombosis (BSHT) Annual Scientific Meeting
Read more
Presentation
January 18, 2023
July 22, 2025

HMB-001 A Novel Bispecific Antibody Accumulating and Targeting Endogenous FVIIa to Activated Platelets for Subcutaneous Prophylaxis in Multiple Bleeding Disorders Including Glanzmann Thrombasthenia

Read more
Presentation
June 1, 2022
July 22, 2025

EAHAD 2022: HMB-001 A novel bispecific antibody with potential for subcutaneous prophylactic treatment of multiple bleeding disorders initial focus on Glanzmann Thrombasthenia (GT)

Presented at 15th Annual Congress of the European Association of Haemophilia and Allied Disorders
Read more
Presentation
June 1, 2022
July 22, 2025

PB0719 The Novel Bispecific Antibody HMB-001 Enhances the Haemostatic Response in Models of Glanzmann Thrombasthenia by Targeting FVIIa to Activated Platelets

Read more
Publication
January 22, 2026
February 6, 2026

HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for Treatment of Von Willebrand Disease

Häger M, Zivkovic M, Gandhi PS, et al. HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for Treatment of Von Willebrand Disease. Blood Adv. 2026; bloodadvances.2025018516.
Read more
Publication
November 15, 2024
July 9, 2025

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study

Khair K, Fletcher S, Jenner K, Holland M. Haemophilia. 2024; 30: 1373–1382.
Read more
Publication
October 8, 2024
July 9, 2025

Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study

Khair, Kate et al. Research and Practice in Thrombosis and Haemostasis, Volume 8, Issue 7, 102586
Read more
Publication
February 8, 2024
July 9, 2025

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders

Gandhi, P.S., Zivkovic, M., Østergaard, H. et al. Nat Cardiovasc Res 3, 166–185 (2024).
Read more
Publication
January 22, 2026
February 6, 2026

HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for Treatment of Von Willebrand Disease

Häger M, Zivkovic M, Gandhi PS, et al. HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for Treatment of Von Willebrand Disease. Blood Adv. 2026; bloodadvances.2025018516.
Read more
Publication
November 15, 2024
July 9, 2025

One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study

Khair K, Fletcher S, Jenner K, Holland M. Haemophilia. 2024; 30: 1373–1382.
Read more
Publication
October 8, 2024
July 9, 2025

Bleeding and quality of life in people with Glanzmann thrombasthenia—insights from the Glanzmann’s 360 study

Khair, Kate et al. Research and Practice in Thrombosis and Haemostasis, Volume 8, Issue 7, 102586
Read more
Publication
February 8, 2024
July 9, 2025

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders

Gandhi, P.S., Zivkovic, M., Østergaard, H. et al. Nat Cardiovasc Res 3, 166–185 (2024).
Read more